Download PDF
Zeitschrift für Phytotherapie 2010; 31(6): 299-305
DOI: 10.1055/s-0030-1262407
Übersicht
Rhapontikrhabarber
© Hippokrates Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Rhapontikrhabarberwurzel-Extrakt ERr 731® bei Wechseljahresbeschwerden

Peter W. Heger
Further Information

Publication History

Publication Date:
04 January 2011 (online)

    Permissions and Reprints

Zusammenfassung

Der Rhapontikrhabarberwurzel-Extrakt ERr 731® hat in bis zu 2-jährigen Studien seine Wirksamkeit und Sicherheit in der Behandlung von Wechseljahresbeschwerden belegt. Hitzewallungen wurden nach 8 und 12 Wochen, gemessen mit dem HFWWS, stärker reduziert, als in niedrig dosierten Hormontherapien.

Summary

Special extract ERr 731® from the roots of Rheum rhaponticum for the treatment of menopausal symptoms Clinical studies entailing two-year application of ERr 731® have proved its efficacy and safety in the treatment of menopausal symptoms. For example, after 8 and 12 weeks ERr 731® has been shown to severely reduce menopausal hot flushes measured by Hot Flush Weekly Weighted Score (HFWWS) compared to low-dose hormone therapy.

Schlüsselwörter

Rheum rhaponticum - Perimenopause - Hot Flush Weekly Weighted Score (HFWWS) - Menopause Rating Scale - Anxiety Inventory Scale - Depression Inventory Scale

Key words

Rheum rhaponticum - Perimenopause - Hot Flush Weekly Weighted Score (HFWWS) - Menopause Rating Scale - Anxiety Inventory Scale - Depression Inventory Scale

Literatur

  • 1 European Medicines Agency .Community herbal monograph on Rheum palmatum L. and Rheum officinale Baillon, radix. EMEA/HMPC 2007: 189624
    Google Scholar
  • 2 Kaszkin-Bettag M. Vollmer G. Rettenberger R. Heger P W. Rhapontikrhabarberwurzel zur Behandlung von menopausalen Beschwerden.  Erfahrungsheilk. 2009;  58 70-77
    PubMedGoogle Scholar
  • 3 Heger M. Ventskovskiy B M. Borzenko I et al.. Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: A 12-week randomized, double-blind, placebo-controlled trial.  Menopause. 2006;  13 744-759
    CrossrefPubMedGoogle Scholar
  • 4 Schulz V. Sibirischer Rhabarber bei klimakterischen Beschwerden.  Z Phytother. 2007;  28 24-25
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Hauser G A. Potthoff P. Rosemeier P J. Schneider H PG. Die Selbstbeurteilungs-Skala für klimakterische Beschwerden (Menopause Rating Scale II).  J Menopause. 1999;  6 12-15
    PubMedGoogle Scholar
  • 6 Potthoff P. Heinemann L A. Schneider H P et al.. Menopause-Rating-Skala (MRS II): Methodische Standardisierung in der deutschen Bevölkerung.  Zentralbl Gynakol. 2000;  122 280-286 http://www.menopause-rating-scale.info
    PubMedGoogle Scholar
  • 7 Kraft K. Stange R. Lehrbuch Naturheilverfahren. Stuttgart: Hippokrates; 2010: 609
    Google Scholar
  • 8 Panay N. Ylikorkala O. Archer D F et al.. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief.  Climacteric. 2007;  10 120-131
    CrossrefPubMedGoogle Scholar
  • 9 Kaszkin-Bettag M. Ventskovskiy B M. Kravchenko A et al.. The special extract ERr 731 of the roots of Rheum rhaponticum decreases anxiety and improves health state and general well-being in perimenopausal women.  Menopause. 2007;  14 270-283
    CrossrefPubMedGoogle Scholar
  • 10 Kaszkin-Bettag M. Rettenberger R. Heger P W. Der Spezialextrakt ERr 731 aus der Wurzel des Rhapontikrhabarbers (Rheum rhaponticum): Wirksamkeit bei Kopfschmerz/ Migräne und weiteren klimakterischen Beschwerden bei Frauen in der Perimenopause.  Schweizer Zeitschr Phytother. 2007;  2 24-30
    PubMedGoogle Scholar
  • 11 Hasper I. Ventskovskiy B M. Rettenberger R et al.. Long-term efficacy and safety of the special extract ERr 731 of Rheum rhaponticum in perimenopausal women with climacteric complaints.  Menopause. 2009;  16 117-131
    CrossrefPubMedGoogle Scholar
  • 12 Kaszkin-Bettag M. Hasper I. Heger P W. Spezialextrakt ERr 731® aus der Rhapontikrhabarberwurzel bei menopausalen Beschwerden, Langzeitstudie bestätigt Wirksamkeit.  Schweizer Zeitschr Phytother. 2008;  8 9-12
    PubMedGoogle Scholar
  • 13 Notelovitz M. Lenihan J P. McDermott M et al.. Initial 17ß-Estradiol dose for treating vasomotor symptoms.  Obstet Gynecol. 2000;  95 726-731
    CrossrefPubMedGoogle Scholar
  • 14 Kaszkin-Bettag M. Ventskovskiy B. Solskyy S et al.. Confirmation of the efficacy of ERr 731® in perimenopausal women with menopausal symptoms.  Altern Ther Health Med. 2009;  15 24-34
    PubMedGoogle Scholar
  • 15 Bachmann C. Bestätigung der Wirksamkeit von ERr 731 bei perimenopausalen Frauen mit menopausalen Beschwerden.  Schweizer Zeitschr Phytother. 2009;  6 18-20
    PubMedGoogle Scholar
  • 16 Heinemann L A. Potthoff P. Schneider H P. International versions of the Menopause Rating Scale.  Health Qual Life Outcomes. 2003;  1 28
    CrossrefPubMedGoogle Scholar
  • 17 Heinemann K. Ruebig A. Potthoff P et al.. The Menopause Rating Scale (MRS) scale: a methodological review.  Health Qual Life Outcomes. 2004;  2 45
    CrossrefPubMedGoogle Scholar
  • 18 Dinger J. Zimmermann T. Heinemann L A. Stoehr D. Quality of life and hormone use: new validation results of MRS scale.  Health Qual Life Outcomes. 2006;  4 32
    CrossrefPubMedGoogle Scholar
  • 19 Medical Products Agency (Lakemedelsverket) Sweden .Public assessment report, scientific discussion, Eviana/Activelle. SE/H/150/02/MR; 2008
    Google Scholar
  • 20 European Medicines Agency (EMA) .Activelle, article 29 referral, annex I (Liste der Arzneimittelnamen), Annex II (Wissenschaftliche Schlussfolgerungen), Annex III (Zusammenfassung der Merkmale des Arzneimittels). 25.09.2009
    Google Scholar
  • 21 Novo Nordisk Canada Inc .Activelle LD Product Monograph 0,5 mg Estradiol and 0,1 mg NETA. Date of Revision 17.04.2008: page 27 of 38
    Google Scholar
  • 22 ERr 004-DB Clinical Trial Report
  • 23 Beck A T. Epstein N. Brown G. Steer R A. An inventory for measuring clinical anxiety: Psychometric properties.  J Consult Clin Psychol. 1988;  56 893-897
    CrossrefPubMedGoogle Scholar
  • 24 Beck A T. Steer R A. Brown G K. BDI-II Manual. San Antonio, TX: The Psychological Corporation; 1996
    Google Scholar
  • 25 Beer A M. Kneis K C. Rettenberger R et al.. Wirksamkeit von Phytoestrol® N (Extrakt Rheum rhaponticum ERr 731) bei klimakterischen Beschwerden: Ergebnisse einer sechsmonatigen, prospektiven Anwendungsbeobachtung mit Phytoestrol® N.  J Menopause. 2007;  3 8-15
    PubMedGoogle Scholar
  • 26 Kaszkin-Bettag M. Beck S. Richardson A et al.. Efficacy of the special extract ERr 731 from rhapontic rhubarb for menopausal complaints: A 6-month open observational study.  Altern Ther Health Med. 2008;  14 32-38
    PubMedGoogle Scholar
  • 27 Schulz V. AWB mit 363 peri- und postmenopausalen Frauen belegt Verträglichkeit und Wirksamkeit.  Z Phytother. 2009;  30 178-179
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 European Medicines Agency .Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. EMEA/CHMP/021/097, Rev. 1; 2005, http://www.emea.europa.eu/pdfs/human/ewp/002197en.pdf
    Google Scholar
  • 29 Chlebowski R T. Anderson G L. Gass M et al.. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.  J Am Med Assoc. 2010;  304 1684-1692
    CrossrefPubMedGoogle Scholar
  • 30 Grady D. Breast cancer seen as riskier with hormone. Interview mit Rowan Chlebowski.  New York Times. 2010;  http://www.nytimes.com/2010/10/20/health/20hormone.html?_r=1&scp=1&sq=chlebowski&st=cse
    PubMedGoogle Scholar
  • 31 Obi N. Pflanzenpräparate bei Wechseljahresbeschwerden und Brustkrebsrisiko – Datenanalyse einer populationsbezogenen Fall-Kontroll-Studie. Saarbrücken: Südwestdt Verlag für Hochschulschriften; 2009: 1-64
    Google Scholar
  • 32 Obi N. Chang-Claude J. Berger J et al.. The use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case-control study.  Cancer Epidemiol Biomarkers Prev. 2009;  18 2207-2213
    CrossrefPubMedGoogle Scholar
  • 33 Becher H. Kostev K. Schröder-Bernhardi D. Validity and representativeness of the »Disease Analyzer« patient database for use in pharmacoepidemiological and pharmacoeconomic studies.  Int J Clin Pharmacol Ther. 2009;  47 617-626
    CrossrefPubMedGoogle Scholar
  • 34 Zepelin H H. Meden H. Kostev K et al.. Isopropanolic black cohosh extract and recurrence-free survival after breast cancer.  Int J Clin Pharmacol Ther. 2007;  45 143-154
    PubMedGoogle Scholar
  • 35 Yue W. Wang J P. Li Y et al.. Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms.  Int J Cancer. 2010;  127 1748-1757
    CrossrefPubMedGoogle Scholar
  • 36 Möller F. Zierau O. Jandausch A et al.. Subtype-specific activation of estrogen receptors by a special extract of Rheum rhaponticum (ERr 731), its aglycones and structurally related compounds in U2OS human osteosarcoma cells.  Phytomedicine. 2007;  14 716-726
    CrossrefPubMedGoogle Scholar
  • 37 Wober J. Möller F. Richter T et al.. Activation of estrogen receptor-beta by a special extract of Rheum rhaponticum (ERr 731), its aglycones and structurally related compounds.  J Steroid Biochem Mol Biol. 2007;  107 191-201
    CrossrefPubMedGoogle Scholar
  • 38 Zhao C. Matthews J. Tujague M et al.. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells.  Cancer Res. 2007;  67 3955-3962
    CrossrefPubMedGoogle Scholar
  • 39 McDonnel D P. Wardell S E. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.  Curr Opin Pharmacol. 2010;  10 1-9
    CrossrefPubMedGoogle Scholar
  • 40 Lindberg K. Ström A. Lock J G et al.. Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1 levels and enhances adhesion of breast cancer cells.  J Cell Physiol. 2010;  222 156-167
    CrossrefPubMedGoogle Scholar
  • 41 Hartman J. Ström A. Gustaffsson J A. Estrogen receptor beta in breast cancer diagnostic and therapeutic implications.  Steroids. 2009;  74 635-641
    CrossrefPubMedGoogle Scholar
  • 42 Zilli M. Grassadonia N. Tinari N et al.. Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer.  Biochim Biophys Acta. 2009;  1795 62-81
    PubMedGoogle Scholar
  • 43 Warner M. Gustafsson J A. The role of estrogen receptor ß (ERß) in malignant diseases a new potential target for antiproliferative drugs in prevention and treatment of cancer.  Biochem Biophys Res Commun. 2010;  396 63-66
    CrossrefPubMedGoogle Scholar
  • 44 Shanle E K. Xu W. Selectively targeting estrogen receptors for cancer treatment.  Adv Drug Deliv Rev. 2010;  [in press]
    PubMedGoogle Scholar
  • 45 Imwalle D B. Gustafsson J A. Rissman E F. Lack of functional estrogen receptor beta influences anxiety behavior and serotonin content in female mice.  Physiol Behav. 2005;  84 157-163
    CrossrefPubMedGoogle Scholar
  • 46 Vollmer G. Papke A. Zierau O. Treatment of menopausal symptoms by an extract from the roots of rhapontic rhubarb: the role of estrogen receptors.  Chin Med. 2010;  5 7
    CrossrefPubMedGoogle Scholar
  • 47 Papke A. Kretzschmar G. Zierau O et al.. Effects of the special extract ERr 731® from Rheum rhaponticum on estrogen-regulated targets in the uterotrophy model of ovariectomized rats.  J Steroid Biochem Mol Biol. 2009;  117 176-184
    CrossrefPubMedGoogle Scholar
  • 48 Kaszkin-Bettag M. Richardson A. Rettenberger R. Heger P W. Long-term toxicity studies in dogs support the safety of the special extract ERr 731 from the roots of Rheum rhaponticum.  Food Chem Toxicol. 2008;  46 1608-1618
    PubMedGoogle Scholar
  • 49 Chemisch-Pharmazeutische Fabrik Göppingen Carl Müller .Phyto-Strol Gebrauchinformation und Fachinformation; 2009. http://www.mueller-goeppingen.de/media/files/BP-Arzneimittel/phyto-strol-2009.pdf
    Google Scholar
  • 50 Huber R. Mind-Maps Phytotherapie. Stuttgart: Hippokrates; 2009: 101
    Google Scholar

Peter W Heger

Health Research Services GmbH

Zeutern

Hofäckerstr. 14

76698 Ubstadt-Weiher

Email: peter.heger@h-r-s.biz

Online

http://dx.doi.org/10.1055/s-0030-1262407

      >